

Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes

Anze Smole

Immunology and Cellular Immunotherapy (ICI) Group, Department of Genetic Toxicology and Cancer Biology, National Institute of Biology, Ljubljana, Slovenia

Radiol Oncol 2022; 56(4): 409-419.

Received 19 October 2022
Accepted 27 October 2022

Correspondence to: Anže Smole, Ph.D., Immunology and Cellular Immunotherapy (ICI) Group, Department of Genetic Toxicology and Cancer Biology, National Institute of Biology, SI-1000 Ljubljana, Slovenia. E-mail: anze.smole@nib.si

Disclosure: A.S. is a co-inventor on PCT International Patent Applications by The Trustees of the University of Pennsylvania, which include discoveries and inventions related to cellular immunotherapies using CAR and TCR T cells.

This is an open access article distributed under the terms of the CC-BY license (<https://creativecommons.org/licenses/by/4.0/>).

Background. Chimeric antigen receptor (CAR) T cell therapy is a clinically approved cancer immunotherapy approach using genetically engineered T cells. The success of CAR T cells has been met with challenges regarding efficacy and safety. Although a broad spectrum of CAR T cell variants and applications is emerging, this review focuses on CAR T cells for the treatment of cancer. In the first part, the general principles of adoptive cell transfer, the architecture of the CAR molecule, and the effects of design on function are presented. The second part describes five conceptual challenges that hinder the success of CAR T cells; immunosuppressive tumour microenvironment, T cell intrinsic properties, tumour targeting, manufacturing cellular product, and immune-related adverse events. Throughout the review, selected current approaches to address these issues are presented.

Conclusions. Cancer immunotherapy with CAR T cells represents a paradigm shift in the treatment of certain blood cancers that do not respond to other available treatment options. Well-trodden paths taken by pioneers led to the first clinical approval, and now the journey continues down lesser-known paths to treat a variety of cancers and other serious diseases with CAR T cells.

Key words: chimeric antigen receptor; adoptive cell therapy; cancer; cellular immunotherapy; gene-engineered immune cells

Introduction

It took a series of ground-breaking ideas and clever experiments to establish the role of the immune system in controlling cancer (reviewed in¹). Current understanding of cancer immunosurveillance also considers the notion that the immune system not only controls tumour formation and growth, but also influences the immunogenicity of the tumour and potential outgrowth. This hypothesis is referred to as cancer immunoediting, in which the three phases of elimination, equilibrium, and escape can be distinguished (reviewed in²). These foundations are important for under-

standing the concepts of cancer immunotherapy, which aims to enhance the immune system's responses to tumour cells.

In the landmark study in 1988³, *ex vivo* expanded autologous tumour-infiltrating lymphocytes (TILs) in combination with human interleukin-2 (rhIL-2) were developed and demonstrated objective responses in patients with metastatic malignant melanoma. In addition, this work provided the unequivocal evidence of tumour-specific T cell mediated immunity leading to cancer recognition and elimination in humans.³ The next milestone was the development of a T cell-based cancer immunotherapy using genetically engineered T cells,




FIGURE 1. The principle of adoptive cellular immunotherapy.

CAR = chimeric antigen receptor; TCR = T-cell receptor

made possible by a better understanding of basic T cell biology and genetic engineering approaches.⁴

Currently, the two most widely used immune receptors that confer tumour specificity and functionality to genetically engineered T cells are a tumour-reactive synthetic chimeric antigen receptor (CAR) and an identified (e.g., from TILs) or further engineered T-cell receptor (TCR). To date, CD19-targeting CAR T cells emerged as the most successful cellular immunotherapy approach. Clinical trials in relapsed or refractory paediatric acute lymphoblastic leukaemia (ALL)⁵⁻⁷ and high-grade B-cell lymphoma in adults⁸⁻¹⁶ have demonstrated that CAR T cell immunotherapy can produce effective, long-lasting, and overall unprecedented clinical responses. CD19-targeting CAR T cells received the U.S. Food and Drug Administration and European Medicines Agency approval in 2017 and 2018, respectively. To date, genetically engineered T cell immunotherapies have mediated unprecedented clinical responses in hematologic malignancies⁵⁻¹⁶ but the efficacy of these therapies is limited in solid tumours and also in certain blood cancers due to several factors, some of which are discussed in this review. In addition, adoptive cellular immunotherapies can cause potentially life-threatening complications such as cytokine release syndrome (CRS) and neurological toxicities.^{17,18}

Nowadays, cellular immunotherapies include exciting research and clinical successes with TILs and T cells genetically modified with TCRs and CARs. In addition, alternative immune cells are being engineered with CARs^{19,20} and CAR T cells

are now being used outside of cancer treatment.²¹⁻²⁷ This review article focuses on CAR T cells to treat cancer. First, the concepts of adoptive cellular immunotherapy with CAR T cells are introduced. Then, the architecture of the CAR molecule is described and how design affects function. Current challenges and limitations regarding efficacy and safety are then presented, focusing on the immunosuppressive tumour microenvironment (TME), T cell intrinsic properties, tumour targeting, cellular product manufacturing and immune-related adverse events. Throughout, this paper presents selected recent next-generation approaches to the development of CAR T cells that have the potential to overcome some of these challenges.

Principles of cellular immunotherapy

Adoptive cell transfer

In its broadest sense, adoptive T cell transfer (ACT) involves the isolation of T lymphocytes from blood and their reinfusion into patients for the treatment of disease. Advances in the understanding of basic mechanisms in T cell biology, including target recognition, T cell activation, signal transduction, role of soluble factors, and co-stimulation signals, have led to a better understanding of T cell function, expansion, and persistence.²⁸ This knowledge has been critical for establishing optimized protocols for *ex vivo* culturing conditions, activation, and expansion. To redirect the specificity of T cells, genetic engineering approaches had to be developed to introduce the genetic cassette encoding TCR or CAR into primary T cells.⁴ These significant advances enabled the development of sophisticated T cell-based therapies such as CAR T cells that transformed oncology.

Current clinical adoptive transfer of CAR T cells involves three steps (Figure 1). (1) Collection of T cells: The patient's own T cells (in the autologous ACT setting), which are the body's primary component for fighting infection and cancer, are first isolated from the blood in a procedure called leukapheresis. These cells express endogenous TCR. (2) *Ex vivo* reprogramming and manufacturing of the cellular product: Primary T cells are first activated using activation beads and then a genetic cassette encoding the CAR molecule is introduced into the primary T cells by viral transduction, which transforms donor T cells into CAR T cells. Introduction of these molecules reprograms T

cells to specifically recognize, target and eliminate cancer cells, while *ex vivo* expansion allows manufacturing of sufficient numbers of CAR T cells. (3) Infusion: Patients are treated with a preparatory chemotherapy and then reinfused with the modified T cells. After *ex-vivo* expansion, the re-programmed cells are infused back to the patient where they find and eliminate the disease.²⁹

Design of a CAR molecule

The Chimera is a creature of Greek mythology that consists of parts of various animals. Based on this analogy, CAR is a molecule that combines the properties of a monoclonal antibody that enables antigen recognition with the components of the TCR that drive T cell signalling and activation. CAR is a molecule composed of different domains, each of which contributes to a specific functionality, and together they effectively redirect T cells to the target of interest and elicit T cell responses (Figure 2).

Design of CAR molecule continues to evolve as we gain more knowledge from basic immunology and clinical trials. First-generation CARs consisted of an extracellular antigen-binding domain, usually in the form of an antibody-derived single-chain variable fragment (scFv) linked to intracellular signalling domains, most often derived from the components of the TCR complex, for example the CD3 zeta chain (CD3 ζ).^{30,31} This molecule was capable of recognizing antigens independent of HLA (human leukocyte antigens) presentation. First-generation CARs provided proof of principle but did not enable long-term T cell persistence and effector responses due to their limited signalling capacity.³² This section describes CAR molecule architecture and its individual domains.

Antigen recognition domain

The specificity of the CAR molecule is defined by the antigen-targeting ectodomain. In most current designs, this is scFv, which is a fusion between variable heavy and variable light chains of an antibody connected by a flexible linker. The affinity of CAR has been shown to have important effects on the functions of CAR T cells. In a clinical study, enhanced CAR T cell expansion and prolonged persistence were observed with a low affinity CD19 CAR compared to CAR T cells with FMC63, a scFv in clinically approved CD19 targeting CAR T cells.³³ Interestingly, in a different study, linker length has also been shown to influence CAR




FIGURE 2. Schematics of the basic CAR architecture.

CAR = chimeric antigen receptor; scFv = single-chain variable fragment

clustering, antigen-independent signalling and function of CAR T cells.³⁴ ScFv have now been designed to target several cell surface molecules associated with cancer, most often proteins, but also glycans such as the aberrant cancer-associated Tn glycoform of MUC1, which is expressed in a variety of cancers.³⁵ Although the mechanism by which binding of CAR to its cognate antigen leads to T cell activation shares key similarities, it also differs substantially from the mechanism by which TCR binding leads to T cell activation. While CARs generally exhibit higher affinity that can also be tuned, the sensitivity is higher in TCRs.³⁶ Currently, CAR T cells that target CD19 (tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel and brexucabtagene autoleucel) and B-cell maturation antigen (BCMA also known as TNFRSF17) (idecabtagene vicleucel, ciltacabtagene autoleucel) are being FDA-approved and marketed^{37,38} while several others are in clinical trials, including CD20, CD22, CD33, CD5, and CD7 (reviewed in³⁹). Some of widely explored targets in solid tumours include alpha folate receptor (FOLR1), human epidermal growth factor receptor 2 (HER2), carcinoembryonic antigen (CEA), ganglioside G2 (GD2), mesothelin, epidermal growth factor receptor variant III (EGFRvIII), mucin1 (MUC1), interleukin-13 receptor subunit alpha-2 (IL13Ra2), prostate specific membrane antigen (PSMA), B7 homolog 3 (B7-H3), epidermal growth factor receptor (EGFR), and fibroblast activation protein (FAP) (reviewed in^{39,40}).

Hinge and transmembrane domain

The scFv domain is connected via a hinge region to the transmembrane (TM) domain. The TM domain is often derived from CD8 or CD28 molecules and functions to anchor CAR in the membrane and facilitate signal transduction. The choice or engineering of TM domain may affect the interactions between CAR molecules themselves⁴¹, or with other endogenous molecules such as CD28.⁴² Innovative designs in hinge and TM domains may provide opportunities to tune CAR signalling.

Co-stimulatory domain

In the clinically approved CARs, the membrane proximal intracellular domain is the co-stimulatory domain. The need for costimulatory domain arose when limited clinical efficacy of the first generation CAR T cells was observed.⁴³ The authors concluded that genetically engineered tumour-reactive T cells are safe but do not persist and that strategies to prolong T cell persistence are needed. The first domain included in the CAR design was the CD28 costimulatory domain, initially alone⁴⁴ and then in combination with CD3 ζ .^{45,46} The CD28 domain provides robust response with an effector phenotype and high levels of secreted IL-2 and tumour lysis activity.⁴⁷ The other widely used co-stimulatory domain introduced into CAR design is CD137 (4-1BB). Compared to CD28, 4-1BB provides improved persistence, shift towards central memory phenotype differentiation, a lower propensity to exhaustion and reduced toxicity.^{15,47,48} A recent comparison between the two marketed products, axicabtagene ciloleucel and tisagenlecleucel examined the differences between CD28 and 4-1BB in relapsed or refractory diffuse large B cell lymphoma and concluded that axicabtagene ciloleucel provides higher efficacy and also a higher toxicity.⁴⁸ Other co-stimulatory domains are also being studied including CD27⁴⁹, ICOS⁵⁰, and OX-40⁵¹, each of which has certain favourable properties. Finally, third generation CARs comprise a combination of two costimulatory domains and some of these have already been tested in clinical trials.⁵² However, excessive stimulation can lead to dysfunctional CAR T cells.⁵³

The design of the second-generation CARs, which includes additional co-stimulatory domains that enhance the expansion, persistence, and effector functions of CAR T cells, has been key to the success of clinical trials. A recent study revealed that CAR T cells persisted for more than ten years

after infusion, with sustained remission in a patient treated with CD19 targeting 4-1BB CAR T in 2010.⁵⁴ Selection of the co-stimulatory domain influences important parameters of CAR T cell therapy including effector function, response kinetics, expansion, differentiation, metabolism and toxicity.⁴⁷ Innovative studies are attempting to address the complexities and unknowns by characterizing multiple intracellular signalling domains in a high throughput manner to identify the CAR designs that have improved functions compared to clinically used CAR T cells.⁵⁵

Activation domain

The distal intracellular domain is CD3 ζ , a signal transduction component of the TCR complex that has been repurposed to drive CAR signalling after recognition of its cognate target. Immunoreceptor tyrosine-based activation motifs (ITAMs) are key motifs in the CD3 ζ domain. When the TCR recognises its target, ITAMs are phosphorylated through a series of molecular interactions mediated by Lck kinase (lymphocyte-specific protein tyrosine kinase). This leads to the recruitment and activation of ZAP-70 (Zeta-chain-associated protein kinase 70), which orchestrates a series of downstream phosphorylation events that result in the complex and highly regulated signal transduction required for T cell activation and effector functions.⁵⁶ CAR signalling resamples key features of TCR signalling but also differs in important ways. Analogous to the “two-step” T cell activation model, CD3 ζ provides signal 1 whereas the co-stimulatory domain provides signal 2. CAR signalling is active area of research in basic T cell biology and has direct importance for the therapeutic implementations. As an alternative to the CD3 ζ , other domains are investigated for CAR T cell therapy including the CD3 ϵ .⁵⁷ An example of rational tuning and calibration of CAR activation and signalling demonstrated that combinatorial mutation of ITAM motifs directs differentiation towards memory T cell states, which translated in improved persistence and therapeutic potency in preclinical mouse models.⁵⁸ Moreover, using the genome editing approach, the TRAC locus was modified in primary human T cells to target cell-surface molecules via their TCR complex, which was reconfigured to use the same targeting component as a corresponding CAR. These HLA-independent TCRs, referred to by the authors as HIT receptors, have been shown to be particularly sensitive compared to CD28-based CARs.⁵⁹

Challenges and opportunities of cellular immunotherapy

The success of CAR T cells is countered by challenges in efficacy in solid tumours⁴⁰ and immune-related adverse events. Underlying causes of limited efficacy include immunosuppressive TME and T cell and tumour intrinsic properties. In addition, the manufacturing of the cellular product and lack of tumour specific targets represent a major challenge. Here, some of these aspects are outlined and selected recent publications are presented that attempt to meet these challenges (Figure 3).

Immunosuppressive tumour microenvironment

Immunosuppressive TME limits the efficacy of CAR T cells by interfering with their function. Various approaches have been developed to address these challenges, including upgrading engineered T cells with the expression of accessory molecules. Pioneering work has been done with tumour infiltrating-lymphocytes (TILs) engineered with inducible expression of the potent immune-enhancing molecule IL-12.⁶⁰ This approach was tested in human clinical trials and clinical activity but also toxicity were observed. Similarly, CAR T cells have been equipped with accessory molecules to counteract various aspects of the hostile immunosuppressive TME. These molecules include IL-18^{61–64}, PD-1⁶⁵, CTLA-4, or TIM3⁶⁶ blocking scFvs and minibodies, CD40L⁶⁷, dominant-negative Fas⁶⁸ or Fas-41BB switch⁶⁹ receptors, pro-inflammatory neutrophil-activating protein (NAP) from *Helicobacter pylori*⁷⁰ and dominant-negative TGF β Receptor.⁷¹ Recently, a pooled knock-in platform has been developed to screen for genetic constructs that can improve T cell functions for effective cell therapies when constitutively over-expressed.⁷² Additional genetic approach coupling expression of effector molecule with specific antigen recognition was developed using a synNotch platform.⁷³ These approaches improve the efficacy of T cell therapy and highlight the need to develop robust and efficient gene expression systems suitable for clinical translation.

Depleting of cells that limit the efficacy of CAR T cells is a viable approach to increase CAR T cell activity in TME. One approach is the depletion of immunosuppressive M2 tumour-associated macrophages (TAMs) by CAR-mediated targeting of a folate receptor β (FR β) positive subset of TAMs that exhibit an immunosuppressive M2-like pro-




FIGURE 3. Challenges of cellular immunotherapy with chimeric antigen receptor (CAR) T cells.

file. CAR T cells eliminated these FR β + TAMs, resulting in recruitment of endogenous tumour-specific CD8+ T cells, improved tumour control, and prolonged survival.⁷⁴

Therefore, overcoming immunosuppressive TME with innovative approaches is an important pillar in improving the activity of CAR T cells.

T cell intrinsic properties

It is becoming increasingly clear that intrinsic T cell dysfunctions, such as T cell exhaustion limit the success of CAR T cells in solid tumours but also in hematologic malignancies that induce dysfunctional T cell states. A recent correlative study examined the determinants of response at genomic, phenotypic and functional levels and demonstrated that clinical efficacy in patients with chronic lymphocytic leukaemia (CLL) treated with CAR T cells is affected by complex intrinsic immune cell functions and dysfunctions.⁷⁵ Chronic stimulation of T cells with an antigen, as occurs also with CAR T cells targeting solid tumours, is an important reason for the dysfunction.⁷⁶ One approach to overcome this problem is a temporary resting period in which the functionality of the CAR T cells is restored.⁷⁷ Innovative approaches

have been developed to maintain functionality of CAR T cells, including overexpression of c-Jun⁷⁸ or a combination of BATF and IRF4.⁷⁹ Recent studies linked the heterogeneity of autologous CAR T cells in terms of cellular and molecular characteristics of the infusion products to differences in efficacy and toxicity following CD19 CAR T therapy.⁸⁰ In a distinct approach, CAR T cells were designed to express interleukin IL-7 and CCL19 to mimic a favourable milieu that forms and maintains T cell zones in lymphoid organs.⁸¹ These upgraded CAR T cells demonstrated enhanced recruitment of T cells and dendritic cells into tumour and augmented therapeutic effects against solid tumours. Favourable effect on differentiation and persistence of CAR T cells has been demonstrated with the constitutive IL-7 receptor⁸², IL-15⁸³, and synthetic receptors combining orthogonal extracellular IL-2 and intracellular IL-9 domains.⁸⁴ In a recent study, overexpression of more than 10,000 barcoded human open reading frames (ORFs) identified positive regulators of T cell function, with the aim of developing improved cellular immunotherapies including CAR T cells.⁸⁵

The intrinsic properties of T cells in the context of CAR T cell therapy require careful study from the perspective of basic immunology. This knowledge is important to overcome the dysfunction that limits the activity of CAR T cells.

Tumour targeting

CD19 is an example of a target that is also expressed on normal cells (B cells), but humans can live with B cell aplasia and appropriate treatment, namely intravenous immunoglobulin (IVIG) treatment, which overcomes antibody deficiencies. However, a major challenge in the development of CAR T cells is to identify targets that are homogeneously expressed at sufficient levels on the surface of tumour cells and are not present on healthy tissues at levels that would cause damage. A tragic example is described in a case report where CAR T cells based on the humanized monoclonal antibody trastuzumab (Herceptin), which recognizes ERBB2, led to the patient's death.⁸⁶ The authors hypothesize that the large number of CAR T cells infiltrated in the lungs and triggered cytokine release after recognizing low levels of ERBB2 on lung epithelial cells.

Acute myeloid leukemia (AML) is a candidate disease for cellular immunotherapy. However, targeting the myeloid marker CD33 in (AML) leads to toxicity from destroying normal myeloid cells.

The authors demonstrated the artificial generation of a leukaemia-specific antigen by deleting CD33 from normal hematopoietic stem and progenitor cells (HSPCs), generating a hematopoietic system resistant to CD33-targeted therapy and enabling specific targeting of AML with CAR T cells.⁸⁷ In this approach, the host was genetically engineered to avoid on-target and off-tumour toxicity.

Heterogeneity⁸⁸ and loss of antigen expression on cancer cells under selective pressure of targeted immunotherapy can lead to evasion strategies by cancer cells.⁸⁹ This has sparked the development of CARs with multiple specificities. Examples for hematologic malignancies include a dual CD19 and CD22 CAR T cells expressing two CAR receptors⁹⁰ or CAR T cells with a tandem scFv CAR molecule with dual targeting of CD19 and CD22.^{91,92}

Another approach that allows on demand multiple antigen targeting to mitigate a potential antigen escape in CAR T cell therapy is adapter CAR platform. One example is the universal immune receptor based on SpyCatcher-SpyTag chemistry. The SpyCatcher immune receptor redirects primary human T cells upon adding SpyTag-labeled targeting ligands.⁹³ Another example is the so-called SUPRA CAR, a split-CAR design that allows the development of CAR T cells with multiple features and provides the ability to switch targets without re-engineering the T cells.⁹⁴

TCRs have been shown to enable targeting of neoantigens⁹⁵⁻⁹⁶ and recently CARs have also been developed that specifically target peptides derived from intracellular proteins presented by HLAs.⁹⁹ These results demonstrate that CAR T cells are not limited to recognizing molecules expressed on the surface, but can now be engineered to recognize intracellular targets presented by the HLAs, which mimics recognition by TCRs. This significantly increases the potential pool of CAR T targets.

Tumour targeting represents a challenge and an opportunity for innovative approaches and advances will be necessary to develop CAR T cell therapies for new disease indications, particularly in solid tumours.

Manufacturing cellular product

The manufacturing process, which involves the collection of autologous T cells and the generation of CAR T cells for each individual patient, is expensive and complex from an infrastructural and logistical perspective. In addition, unexpected challenges can emerge with some of the existing pipelines. One such example is the discovery that

the lentivirally delivered CAR gene was inadvertently introduced into a single leukemic B cell during T cell manufacturing. This anti-CD19 CAR molecule then bound the CD19 epitope on the surface of the same leukemic cells, which masked it from being recognized by the CD19-targeting CAR T cells, resulting in relapse.¹⁰⁰ Therefore, there is great interest in optimizing the manufacturing of the cellular product to make it safer, more effective and broadly available.

Recent study presented the shortened process of manufacturing of non-activated CAR T cells with improved functionality.¹⁰¹ Another study investigated the approach where CAR T cells have been manufactured from the defined CD4⁺ and CD8⁺ T cell subsets and infused in a defined CD4⁺: CD8⁺ composition.¹⁰² Recent study investigated the efficacy and safety of CAR T cells generated from preselected naïve/stem memory T cells, observing a superior safety and efficacy profile compared to unselected bulk T cells.¹⁰³ In addition, alternative sources of donor T cells are being explored, including allogeneic off-the-shelf approaches.^{104,105} Recently, the first human clinical trials were reported with CRISPR/Cas9-engineered T cells that edited PD-1¹⁰⁶ or even demonstrated multiplex CRISPR/Cas9 editing of the endogenous T cell receptor and PD-1.¹⁰⁷

Currently CAR T cells are produced via lentiviral or retroviral transduction, where integration of a gene encoding CAR is semi random and poses certain risks and challenges. Recent studies have demonstrated that genome editing technologies can be used for CRISPR/Cas9-mediated targeted integration of a CAR into an endogenous locus via homology-directed repair (HDR) and an adeno-associated virus (AAV) vector as a HDR donor template.^{108,109} Further, a non-viral strategy using a double stranded DNA as a HDR donor template for CRISPR/Cas9-mediated targeted integration has been demonstrated.¹¹⁰ CAR T cells generated with non-viral targeted integration have even been tested in a clinical trial.¹¹¹ Finally, approaches to generate CAR T cells *in vivo* are also being explored.¹¹²

Bringing the manufacture of cellular products to a level that enabled clinical approval required extensive efforts by pioneers and now continues to represent an area of opportunity to make CAR T cells safer, more effective, and broadly available.

Immune-related adverse events

Unfortunately, adoptive cancer immunotherapy carries safety risks such as cytokine release syn-

drome (CRS) and neurologic toxicities¹¹³, that have led to life-threatening complications.¹⁷ Current management strategies include systemic use of the antibody tocilizumab, which blocks IL-6 receptor.¹¹⁴ CRS and neurotoxicity are the two main toxicities associated with clinically used CD19-targeting therapies. B-cell aplasia is on-target, off-tumour adverse effect of CARs that target B-cell differentiation antigens such as CD19¹⁷ and can be effectively managed by IVIG, as mentioned earlier in the paper. Further, on-target off-tumour toxicity can have devastating effects⁸⁶ as described in previous sections.

A recent study illuminated a contributor to severe neurotoxicity observed in a subset of patients treated with CD19-targeting therapies. The authors show that brain mural cells, which surround the endothelium and are critical for the integrity of the blood-brain-barrier, express CD19, implying that on-target off-tumour toxicities may occur.¹¹⁵

Several approaches are being developed to mitigate toxicities, including platforms in which the activity of CAR T cells can be regulated by genetically encoded transient functions in a combination with the small molecules¹¹⁶⁻¹¹⁸ or targeting ligands.^{93,94} Suicide switches based on inducible caspase-9¹¹⁹ or on expression of surface molecules, such as a truncated version of epidermal growth factor receptor (EGFRt) are being developed. In the latter case, EGFRt is expressed together with CAR on the surface of T cells, so that CAR T cells can be eliminated by addition of an antibody targeting EGFRt.¹²⁰

SynNotch enabled AND-gate combinatorial targeting, in which the synNotch receptor first recognized one tumour antigen, which led to the release of a transcriptional activator domain to drive expression of a CAR targeting another tumour antigen.¹²¹

New insights into the biology of CAR T cells, experience from clinical trials, and advances in engineering approaches now provide the basis for making CAR T cells safer while maintaining their efficacy.

Conclusions

This review article focuses on CAR T cells for cancer immunotherapy. However, it is important to note that cellular immunotherapy using TILs^{122,123} or T cells with engineered TCRs has achieved remarkable success in clinical studies in solid tumours and established approaches to target intra-

cellular antigens presented in the context of major histocompatibility complex (MHC) molecules including neoantigens.^{95–97} The success of CAR T cells in treating cancer has led to their use outside of cancer treatment, including autoimmunity^{21–23}, infections^{24,25}, senescence-associated pathologies²⁶, and cardiac fibrosis.^{27,112} Several cell types including Natural Killer (NK)¹⁹ cells and macrophages²⁰ are being explored as alternatives to T cells that have certain advantages and provide new features. Cancer immunotherapy with CAR T cells represents a paradigm shift in the treatment of certain blood cancers that do not respond to other available treatment options. Well-trodden paths blazed by pioneers led to the first FDA and EMA approval, and the journey now continues on lesser-known paths to treat a variety of cancers and other serious diseases with CAR T cells.

Acknowledgments

A.S. thanks J. Pohar and K. Butina Ogorelec for reviewing and providing valuable feedback on the manuscript. A.S. received funding from Slovenian Research Agency (ARRS) for Project J3-3084 and Program P1-0245 and from Research fund of the National Institute of Biology for Project 10ICIGEN (ICI). Figures created with BioRender.com

References

- Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. *Annu Rev Immunol* 2011; **29**: 235-71. doi: 10.1146/annurev-immunol-031210-101324
- Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science* 2011; **331**: 1565-70. doi: 10.1126/science.1203486
- Rosenberg SA, Packard BS, Aebbersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. *N Engl J Med* 1988; **319**: 1676-80. doi: 10.1056/nejm198812223192527
- Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. *Nature* 2017; **545**: 423-31. doi: 10.1038/nature22395
- Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *N Engl J Med* 2013; **368**: 1509-18. doi: 10.1056/NEJMoa1215134
- Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N Engl J Med* 2018; **378**: 439-48. doi: 10.1056/nejmoa1709866
- Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. *Lancet* 2015; **385**: 517-28. doi: 10.1016/S0140-6736(14)61403-3
- Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. *N Engl J Med* 2017; **28**: 2545-54. doi: 10.1056/NEJMoa1708566
- Sommermeier D, Hudecek M, Kosasih PL, Gogshvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. *Leukemia* 2016; **30**: 492-500. doi: 10.1038/leu.2015.247
- Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. *Blood* 2011; **118**: 4817-28. doi: 10.1182/blood-2011-04-348540
- Porter DL, Levine BL, Kalos M, Bagg A, June CH, Levine BL, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *N Engl J Med* 2011; **365**: 725-33. doi: 10.1056/nejmoa1103849
- Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *N Engl J Med* 2017; **377**: 2531-44. doi: 10.1056/nejmoa1707447
- Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. *N Engl J Med* 2019; **380**: 45-56. doi: 10.1056/nejmoa1804980
- Abramson JS, McGree B, Sarah Noyes N, Sean Plummer B, Curtis Wong B, Chen YB, et al. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. *N Engl J Med* 2017; **377**: 783-4. doi: 10.1056/NEJM1704610
- Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. *Sci Transl Med* 2011; **3**: 95ra73. doi: 10.1126/scitranslmed.3002842
- Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. *Blood* 2010; **116**: 4099-102. doi: 10.1182/blood-2010-04-281931
- Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. *Nat Rev Clin Oncol* 2017; **15**: 47-62. doi: 10.1038/nrclinonc.2017.148
- Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. *Blood Rev* 2019; **34**: 45-55. doi: 10.1016/j.blre.2018.11.002
- Liu E, Marin D, Banerjee P, MacApinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. *N Engl J Med* 2020; **382**: 545-53. doi: 10.1056/nejmoa1910607
- Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. *Nat Biotechnol* 2020; **38**: 947-53. doi: 10.1038/s41587-020-0462-y
- Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. *Science* 2016; **353**: 179-84. doi: 10.1126/science.aaf6756
- Mackensen A, Müller F, Mougjakakos D, Böltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. *Nat Med* 2022; **28**: 2124-32. doi: 10.1038/s41591-022-02017-5
- Mougjakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboulis S, et al. CD19-Targeted CAR T cells in refractory systemic lupus erythematosus. *N Engl J Med* 2021; **385**: 567-9. doi: 10.1056/nejmc2107725
- Maldini CR, Gayout K, Leibman RS, Dopkin DL, Mills JP, Shan X, et al. HIV-resistant and HIV-specific CAR-modified CD4+ T cells mitigate HIV disease progression and confer CD4+ T cell help in vivo. *Mol Ther* 2020; **28**: 1-15. doi: 10.1016/j.jymthe.2020.05.012
- Maldini CR, Claiborne DT, Okawa K, Chen T, Dopkin DL, Shan X, et al. Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo. *Nat Med* 2020; **26**: 1776-87. doi: 10.1038/s41591-020-1039-5
- Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, et al. Senolytic CAR T cells reverse senescence-associated pathologies. *Nature* 2020; **583**: 127-32. doi: 10.1038/s41586-020-2403-9
- Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, et al. Targeting cardiac fibrosis with engineered T cells. *Nature* 2019; **573**: 430-3. doi: 10.1038/s41586-019-1546-z
- Kalos M, June CH. Adoptive T Cell Transfer for cancer immunotherapy in the era of synthetic biology. *Immunity* 2013; **39**: 49-60. doi: 10.1016/j.immuni.2013.07.002

29. June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC, O'Connor RS, et al. CAR T cell immunotherapy for human cancer. *Science* 2018; **1365**: 1361-5. doi: 10.1126/science.aar6711
30. Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. *Biochem Biophys Res Commun* 1987; **149**: 960-8. doi: 10.1016/0006-291X(87)90502-X
31. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. *Proc Natl Acad Sci U S A* 1993; **90**: 720-4. doi: 10.1073/pnas.90.2.720
32. Brocker T, Karjalainen K. Signals through T cell receptor- ζ chain alone are insufficient to prime resting T lymphocytes. *J Exp Med* 1995; **181**: 1653-9. doi: 10.1084/jem.181.5.1653
33. Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. *Nat Med* 2019; **25**: 1408-14. doi: 10.1038/s41591-019-0549-5
34. Singh N, Frey N V, Engels B, Barrett DM, Shestova O, Ravikumar P, et al. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. *Nat Med* 2021; **27**: 842-50. doi: 10.1038/s41591-021-01326-5
35. Posey AD, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. *Immunity* 2016; **44**: 1444-54. doi: 10.1016/j.immuni.2016.05.014
36. Harris DT, Kranz DM. Adoptive T Cell therapies: a comparison of T cell receptors and chimeric antigen receptors. *Trends Pharmacol Sci* 2015; **37**: 220-30. doi: 10.1016/j.tips.2015.11.004
37. Bashor CJ, Hilton IB, Bandukwala H, Smith DM, Veishe O. Engineering the next generation of cell-based therapeutics. *Nat Rev Drug Discov* 2022; **21**: 655-75. doi: 10.1038/s41573-022-00476-6
38. Mullard A. FDA approves second BCMA-targeted CAR-T cell therapy. *Nat Rev Drug Discov* 2022; **21**: 249. doi: 10.1038/d41573-022-00048-8
39. MacKay M, Afshinnkoo E, Rub J, Hassan C, Khunte M, Baskaran N, et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. *Nat Biotechnol* 2020; **38**: 233-44. doi: 10.1038/s41587-019-0329-2
40. Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. *Cell Res* 2016; **27**: 38-58. doi: 10.1038/cr.2016.154
41. Elazar A, Chandler NJ, Davey AS, Weinstein JY, Nguyen J V, Trenker R, et al. De novo-designed transmembrane domains tune engineered receptor functions. *Elife* 2022; **11**: 1-29. doi: 10.7554/eLife.75660
42. Muller YD, Nguyen DP, Ferreira LMR, Ho P, Raffin C, Valencia RVB, et al. The CD28-transmembrane domain mediates chimeric antigen receptor heterodimerization with CD28. *Front Immunol* 2021; **12**: 639818. doi: 10.3389/fimmu.2021.639818
43. Kershaw MH, Westwood J a, Parker LL, Wang G, Eshhar Z, Mavroukakis S a, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. *Clin Cancer Res* 2006; **12**: 6106-15. doi: 10.1158/1078-0432.CCR-06-1183
44. Krause A, Guo HF, Latouche JB, Tan C, Cheung NK V, Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. *J Exp Med* 1998; **188**: 619-26. doi: 10.1084/jem.188.4.619
45. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR ζ /CD28 receptor. *Nat Biotechnol* 2002; **20**: 70-5. doi: 10.1038/nbt0102-70
46. Hombach A, Wiczarkowicz A, Marquardt T, Heuser C, Usai L, Pohl C, et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 ζ signaling receptor molecule. *J Immunol* 2001; **167**: 6123-31. doi: 10.4049/jimmunol.167.11.6123
47. Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T Cells. *Immunity* 2016; **44**: 380-90. doi: 10.1016/j.immuni.2016.01.021
48. Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. *Nat Med* 2022; **28**: 2145-54. doi: 10.1038/s41591-022-01969-y
49. Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. *Blood* 2012; **119**: 696-706. doi: 10.1182/blood-2011-03-344275
50. Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, et al. ICOS-based chimeric antigen receptors program bipolar TH17/ TH1 cells. *Blood* 2014; **124**: 1070-80. doi: 10.1182/blood-2013-10-535245
51. Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells. *Oncoimmunology* 2012; **1**: 458-66. doi: 10.4161/onci.19855
52. Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, et al. In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell Non-Hodgkin's lymphomas. *Mol Ther* 2018; **26**: 2727-37. doi: 10.1016/j.ymthe.2018.09.009
53. Wijewarnasuriya D, Bebernitz C, Lopez AV, Rafiq S, Brentjens RJ. Excessive costimulation leads to dysfunction of adoptively transferred T cells. *Cancer Immunol Res* 2020; **18**: 732-42. doi: 10.1158/2326-6066.CIR-19-0908
54. Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MKA, et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. *Nature* 2022; **602**: 503-9. doi: 10.1038/s41586-021-04390-6
55. Gordon KS, Kyung T, Perez CR, Holec P V, Ramos A, Zhang AQ, et al. Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains. *Nat Biomed Eng* 2022; **6**: 855-66. doi: 10.1038/s41551-022-00896-0
56. Love PE, Hayes SM. ITAM-mediated signaling by the T-cell antigen receptor. *Cold Spring Harb Perspect Biol* 2010; **2**: 1-11. doi: 10.1101/cshperspect.a002485
57. Wu W, Zhou Q, Masubuchi T, Shi X, Li H, Xu X, et al. Multiple signaling roles of CD3 ϵ and its application in CAR-T cell therapy. *Cell* 2020; **182**: 855-871. e23. doi: 10.1016/j.cell.2020.07.018
58. Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. *Nat Med* 2019; **25**: 82-8. doi: 10.1038/s41591-018-0290-5
59. Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Pailion N, et al. HLA-independent T cell receptors for targeting tumors with low antigen density. *Nat Med* 2022; **28**: 345-52. doi: 10.1038/s41591-021-01621-1
60. Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. *Clin Cancer Res* 2015; **21**: 2278-88. doi: 10.1158/1078-0432.CCR-14-2085
61. Hu B, Ren J, Luo Y, Scholler J, Zhao Y, June CH, et al. CAR T cells secreting IL18 augment antitumor immunity and increase T cell proliferation and costimulation. *Cell Rep* 2017; **20**: 3025-33. doi: 10.1016/j.celrep.2017.09.002
62. Kunert A, Chmielewski M, Wijers R, Berrevoets C, Abken H, Debets R. Intratumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors. *Oncoimmunology* 2017; **7**: 1-12. doi: 10.1080/2162402X.2017.1378842
63. Chmielewski M, Abken H. CAR T cells releasing IL-18 convert to T-Bet high FoxO1 low effectors that exhibit augmented activity against advanced solid tumors. *Cell Rep* 2017; **21**: 3205-19. doi: 10.1016/j.celrep.2017.11.063
64. Zimmermann K, Kuehle J, Dragon AC, Galla M, Kloth C, Rudek LS, et al. Design and characterization of an "all-in-one" lentiviral vector system combining constitutive anti-gd2 car expression and inducible cytokines. *Cancers* 2020; **12**: 1-22. doi: 10.3390/cancers12020375
65. Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. *Nat Biotechnol* 2018; **36**: 847-56. doi: 10.1038/nbt.4195
66. Yin Y, Boesteanu AC, Binder ZA, Xu C, Reid RA, Rodriguez JL, et al. Checkpoint blockade reverses anergy in IL-13R α 2 humanized scFv-based CAR T cells to treat murine and canine gliomas. *Mol Ther Oncolytics* 2018; **11**: 20-38. doi: 10.1016/j.omto.2018.08.002

67. Kuhn NF, Purdon TJ, van Leeuwen DG, Lopez A V, Curran KJ, Daniyan AF, et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. *Cancer Cell* 2019; **35**: 473-88. doi: 10.1016/j.ccell.2019.02.006
68. Yamamoto TN, Lee P-HH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, et al. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. *J Clin Invest* 2019; **129**: 1551-65. doi: 10.1172/JCI121491
69. Oda SK, Anderson KG, Ravikumar P, Bonson P, Garcia NM, Jenkins CM, et al. A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy. *J Exp Med* 2020; **217**: 1-16. doi: 10.1084/jem.20191166
70. Jin C, Ma J, Ramachandran M, Yu D, Essand M. CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumor responses in solid cancers. *Nat Biomed Eng* 2022; **6**: 830-41. doi: 10.1038/s41551-022-00875-5
71. Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. *Nat Med* 2022; **28**: 724-34. doi: 10.1038/s41591-022-01726-1
72. Roth TL, Li PJ, Blaeschke F, Nies JF, Apathy R, Mowery C, et al. Pooled knockin targeting for genome engineering of cellular immunotherapies. *Cell* 2020; **181**: 728-744.e21. doi: 10.1016/j.cell.2020.03.039
73. Roybal KT, Williams JZ, Morsut L, Walker WJ, McNally KA, Lim WA. Engineering T cells with customized therapeutic article engineering T cells with customized therapeutic response programs using synthetic notch receptors. *Cell* 2016; **167**: 419-32. doi: 10.1016/j.cell.2016.09.011
74. Rodriguez-garcia A, Lynn RC, Poussin M, Eiva MA, Shaw LC, Connor RSO, et al. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. *Nat Commun* 2021; **12**: 877. doi: 10.1038/s41467-021-20893-2
75. Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nat Med* 2018; **24**: 563-71. doi: 10.1038/s41591-018-0010-1
76. Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, et al. An NK-like CAR T cell transition in CAR T cell dysfunction. *Cell* 2021; **184**: 6081-6100.e26. doi: 10.1016/j.cell.2021.11.016
77. Weber EW, Parker KR, Sotillo E, Lynn RC, Anbunathan H, Lattin J, et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. *Science* 2021; **372**: eaba1786. doi: 10.1126/science.aba1786
78. Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. *Nature* 2019; **576**: 293-300. doi: 10.1038/s41586-019-1805-z
79. Seo H, González-Avalos E, Zhang W, Ramchandani P, Yang C, Lio CWJ, et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. *Nat Immunol* 2021; **22**: 983-95. doi: 10.1038/s41590-021-00964-8
80. Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. *Nat Med* 2020; **26**: 1878-87. doi: 10.1038/s41591-020-1061-7
81. Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. *Nat Biotechnol* 2018; **36**: 346-51. doi: 10.1038/nbt.4086
82. Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, et al. Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirection T cells. *Cancer Discov* 2017; **7**: 1238-47. doi: 10.1158/2159-8290.CD-17-0538
83. Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo CF, et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. *Cancer Immunol Res* 2019; **7**: 759-72. doi: 10.1158/2326-6066.CIR-18-0466
84. Kalbasi A, Siurala M, Su LL, Tariveranmohabadi M, Picton LK, Ravikumar P, et al. Potentiating adoptive cell therapy using synthetic IL-9 receptors. *Nature* 2022; **607**: 360-5. doi: 10.1038/s41586-022-04801-2
85. Legut M, Gajic Z, Guarino M, Daniloski Z, Rahman JA, Xue X, et al. A genome-scale screen for synthetic drivers of T cell proliferation. *Nature* 2022; **603**: 728-35. doi: 10.1038/s41586-022-04494-7
86. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2. *Mol Ther* 2010; **18**: 843-51. doi: 10.1038/mt.2010.24
87. Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. *Cell* 2018; **173**: 1439-1453.e19. doi: 10.1016/j.cell.2018.05.013
88. Qazi MA, Vora P, Venugopal C, Sidhu SS, Moffat J, Swanton C, et al. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. *Ann Oncol* 2017; **28**: 1448-56. doi: 10.1093/annonc/mdx169
89. Ruella M, Maus M V. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. *Comput Struct Biotechnol J* 2016; **14**: 357-62. doi: 10.1016/j.csbj.2016.09.003
90. Cordoba S, Onuoha S, Thomas S, Pignataro DS, Hough R, Ghorashian S, et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. *Nat Med* 2021; **27**: 1797-805. doi: 10.1038/s41591-021-01497-1
91. Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. *Nat Med* 2018; **24**: 20-8. doi: 10.1038/nm.4441
92. Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. *Nat Med* 2021; **27**: 1419-31. doi: 10.1038/s41591-021-01436-0
93. Minutolo NG, Sharma P, Poussin M, Shaw LC, Brown DP, Hollander EE, et al. Quantitative control of gene-engineered T-cell activity through the covalent attachment of targeting ligands to a universal immune receptor. *J Am Chem Soc* 2020; **142**: 6554-68. doi: 10.1021/jacs.9b11622
94. Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. *Cell* 2018; **173**: 1426-1438.e11. doi: 10.1016/j.cell.2018.03.038
95. Tran E, Robbins PF, Lu Y-C, Prickett TD, Gartner JJ, Jia L, et al. T-cell transfer therapy targeting mutant KRAS in cancer. *N Engl J Med* 2016; **375**: 2255-62. doi: 10.1056/NEJMoa1609279
96. Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, et al. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. *J Exp Med* 2018; **215**: 141-57. doi: 10.1084/jem.20171046
97. Leidner R, Sanjuan Silva N, Huang H, Sprott D, Zheng C, Shih Y-P, et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. *N Engl J Med* 2022; **386**: 2112-9. doi: 10.1056/nejmoa2119662
98. Bear AS, Blanchard T, Cesare J, Ford MJ, Richman LP, Xu C, et al. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. *Nat Commun* 2021; **12**: 1-16. doi: 10.1038/s41467-021-24562-2
99. Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, et al. Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. *Nature* 2021; **599**: 477-84. doi: 10.1038/s41586-021-04061-6
100. Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. *Nat Med* 2018; **24**: 1499-503. doi: 10.1038/s41591-018-0201-9
101. Ghassemi S, Durgin JS, Nunez-Cruz S, Patel J, Leferovich J, Pinzone M, et al. Rapid manufacturing of non-activated potent CAR T cells. *Nat Biomed Eng* 2022; **6**: 118-28. doi: 10.1038/s41551-021-00842-6
102. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+CD8+ composition in adult B cell ALL patients. *J Clin Invest* 2016; **126**: 2123-38. doi: 10.1172/JCI85309
103. Arcangeli S, Bove C, Mezzanotte C, Camisa B, Falcone L, Manfredi F, et al. CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. *J Clin Invest* 2022; **132**: e150807. doi: 10.1172/JCI150807

104. Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. 'Off-the-shelf' allogeneic CAR T cells: development and challenges. *Nat Rev Drug Discov* 2020; **19**: 185-99. doi: 10.1038/s41573-019-0051-2
105. Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. *Sci Transl Med* 2017; **9**: 1-9. doi: 10.1126/scitranslmed.aaj2013
106. Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. *Nat Med* 2020; **26**: 732-40. doi: 10.1038/s41591-020-0840-5
107. Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. *Science* 2020; **367**: 1-12. doi: 10.1126/science.aba7365
108. Eyquem J, Mansilla-Soto J, Giavridis T, Van Der Stegen SJC, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. *Nature* 2017; **543**: 113-7. doi: 10.1038/nature21405
109. Dai X, Park JJ, Du Y, Kim HR, Wang G, Errami Y, et al. One-step generation of modular CAR-T cells with AAV-Cpf1. *Nat Methods* 2019; **16**: 247-54. doi: 10.1038/s41592-019-0329-7
110. Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. *Nature* 2018; **559**: 405-9. doi: 10.1038/s41586-018-0326-5
111. Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. *Nature* 2022; **609**: 369-74. doi: 10.1038/s41586-022-05140-y
112. Rurik JG, Tombácz I, Yadegari A, Fernández POM, Shewale S V, Li L, et al. CAR T cells produced in vivo to treat cardiac injury. *Science* 2022; **96**: 91-6. doi: 10.1126/science.abm0594
113. June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles' heel of cancer immunotherapy? *Nat Med* 2017; **23**: 540-7. doi: 10.1038/nm.4321
114. Singh N, Hofmann TJ, Gershenson Z, Levine BL, Grupp SA, Teachey DT, et al. Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. *Cytotherapy* 2017; **19**: 867-80. doi: 10.1016/j.jcyt.2017.04.001
115. Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. *Cell* 2020; **183**: 126-142.e17. doi: 10.1016/j.cell.2020.08.022
116. Wu C-Y, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. *Science* 2015; **350**: aab4077. doi: 10.1126/science.aab4077
117. Juillerat A, Marechal A, Filhol JM, Valton J, Duclert A, Poirot L, et al. Design of chimeric antigen receptors with integrated controllable transient functions. *Sci Rep* 2016; **6**: 1-7. doi: 10.1038/srep18950
118. Giordano-Attianese G, Gainza P, Gray-Gaillard E, Cribioli E, Shui S, Kim S, et al. A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy. *Nat Biotechnol* 2020; **38**: 426-32. doi: 10.1038/s41587-019-0403-9
119. Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. *Leukemia* 2010; **24**: 1160-70. doi: 10.1038/leu.2010.75
120. Paszkiewicz PJ, Fräßle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. *J Clin Invest* 2016; **126**: 4262-72. doi: 10.1172/JCI84813
121. Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. *Cell* 2016; **164**: 1-10. doi: 10.1016/j.cell.2016.01.011
122. Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. *Science* 2015; **350**: 1387-90. doi: 10.1126/science.aad1253
123. Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. *Nat Med* 2018; **1**: 724-30. doi: 10.1038/s41591-018-0040-8